'In vitro' assessments of microencapsulated viable cells as a result of primary bile acid-encapsulated formulation for inflammatory disorders

Mooranian, A; Jones, M; Walker, D; Ionescu, C; Wagle, S; Kovačević, B; Chester, J; Foster, T; Johnston, E; Mikov, M; Al-Salami, H

Journal article

'In vitro' assessments of microencapsulated viable cells as a result of primary bile acid-encapsulated formulation for inflammatory disorders

Abstract:: Background / Aim: Metformin is widely used in type 2 diabetes and exhibits many positive biological effects on pancreatic b-cells and muscle cells, such as supporting insulin release by b-cells and glucose uptake by muscle cells and reducing oxidative stress, particularly due to diabetes-associated hyperglycaemia. Interestingly, for type 1 diabetes, transplantation of healthy b-cells has been proposed as a novel way to replace insulin therapy. Recently, bile acid-formulations containing transplantable b-cells showed best stability. Hence, this study aimed to explore the effects of metformin-bile acid formulations in b-cell encapsulation and on the biological activities of b-cells and muscle-cells. Methods: Two sets of biological effects were examined, using metformin-bile acid formulations, on encapsulated b-cells and on muscle cells exposed to the formulations. Results: Various encapsulated b-cell formulations' cell viability, insulin levels, cellular oxidative stress, cellular inflammatory profile and bioenergetics at the normoand hyperglycaemic states showed differing results based upon the metformin concentration and the inclusion or absence of bile acid. Similar effects were observed with muscle cells. Low ratios of metformin and bile acids showed best biological effects, suggesting a formulation dependent result. The formulations' positive effects were more profound at the hyperglycaemic state suggesting efficient cell protective effects. Conclusion: Overall, metformin had positive impacts on the cells in a concentration-dependent manner, with the addition of chenodeoxycholic acid further improving results.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Mooranian, A., Jones, M., Walker, D., Ionescu, C., Wagle, S., Kovačević, B., Chester, J., Foster, T., Johnston, E., Mikov, M., & Al-Salami, H. (2022). 'In vitro' assessments of microencapsulated viable cells as a result of primary bile acid-encapsulated formulation for inflammatory disorders. Scripta Medica, 53(2), 103–115.

MLA Style

Mooranian, A, et al. “'In Vitro' Assessments of Microencapsulated Viable Cells as a Result of Primary Bile Acid-Encapsulated Formulation for Inflammatory Disorders.” Scripta Medica, vol. 53, no. 2, 2022, pp. 103–15.

Chicago Style

Mooranian, A, M Jones, D Walker, et al. 2022. “'In Vitro' Assessments of Microencapsulated Viable Cells as a Result of Primary Bile Acid-Encapsulated Formulation for Inflammatory Disorders.” Scripta Medica 53 (2): 103–15.
Print